Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.

Leukemia & lymphoma

Williams ME, Connors JM, Dreyling MH, Gascoyne RD, Kahl BS, Leonard JP, Press OW, Wilson WH.
PMID: 21133727
Leuk Lymphoma. 2011 Jan;52(1):24-33. doi: 10.3109/10428194.2010.532893. Epub 2010 Dec 06.

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically characterized by cyclin D1 overexpression as result of the t(11;14) translocation. MCL is biologically and clinically heterogeneous and frequently involves extranodal dissemination. Although MCL is incurable with current...

Cite
Williams ME, Connors JM, Dreyling MH, et al. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2010;52(1):24-33doi: 10.3109/10428194.2010.532893.
Williams, M. E., Connors, J. M., Dreyling, M. H., Gascoyne, R. D., Kahl, B. S., Leonard, J. P., Press, O. W., & Wilson, W. H. (2011). Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leukemia & lymphoma, 52(1), 24-33. https://doi.org/10.3109/10428194.2010.532893
Williams, Michael E, et al. "Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop." Leukemia & lymphoma vol. 52,1 (2011): 24-33. doi: https://doi.org/10.3109/10428194.2010.532893
Williams ME, Connors JM, Dreyling MH, Gascoyne RD, Kahl BS, Leonard JP, Press OW, Wilson WH. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2011 Jan;52(1):24-33. doi: 10.3109/10428194.2010.532893. Epub 2010 Dec 06. PMID: 21133727; PMCID: PMC7357185.
Copy Download .nbib Format: NLM
Progress in mantle-cell lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Martin P, Coleman M, Leonard JP.
PMID: 19075257
J Clin Oncol. 2009 Feb 01;27(4):481-3. doi: 10.1200/JCO.2008.19.5032. Epub 2008 Dec 15.

No abstract available.

Cite
Martin P, Coleman M, Leonard JP. Progress in mantle-cell lymphoma. J Clin Oncol. 2008;27(4):481-3doi: 10.1200/JCO.2008.19.5032.
Martin, P., Coleman, M., & Leonard, J. P. (2009). Progress in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(4), 481-3. https://doi.org/10.1200/JCO.2008.19.5032
Martin, Peter, et al. "Progress in mantle-cell lymphoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 27,4 (2009): 481-3. doi: https://doi.org/10.1200/JCO.2008.19.5032
Martin P, Coleman M, Leonard JP. Progress in mantle-cell lymphoma. J Clin Oncol. 2009 Feb 01;27(4):481-3. doi: 10.1200/JCO.2008.19.5032. Epub 2008 Dec 15. PMID: 19075257.
Copy Download .nbib Format: NLM
Open questions in the management of mantle cell lymphoma.

Cancer treatment reviews

Li ZM, Zucca E, Ghielmini M.
PMID: 23415066
Cancer Treat Rev. 2013 Oct;39(6):602-9. doi: 10.1016/j.ctrv.2012.12.013. Epub 2013 Feb 13.

Mantle cell lymphoma (MCL) is one of the lymphomas with the worse prognosis (median survival 3-5years) as it has an aggressive evolution and at the same time is incurable. Biologically it is characterized by the t(11;14)(q13;q32) translocation leading to...

Cite
Li ZM, Zucca E, Ghielmini M. Open questions in the management of mantle cell lymphoma. Cancer Treat Rev. 2013;39(6):602-9doi: 10.1016/j.ctrv.2012.12.013.
Li, Z. M., Zucca, E., & Ghielmini, M. (2013). Open questions in the management of mantle cell lymphoma. Cancer treatment reviews, 39(6), 602-9. https://doi.org/10.1016/j.ctrv.2012.12.013
Li, Zhi-Ming, et al. "Open questions in the management of mantle cell lymphoma." Cancer treatment reviews vol. 39,6 (2013): 602-9. doi: https://doi.org/10.1016/j.ctrv.2012.12.013
Li ZM, Zucca E, Ghielmini M. Open questions in the management of mantle cell lymphoma. Cancer Treat Rev. 2013 Oct;39(6):602-9. doi: 10.1016/j.ctrv.2012.12.013. Epub 2013 Feb 13. PMID: 23415066.
Copy Download .nbib Format: NLM
Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine.

Hematology/oncology and stem cell therapy

Sandoval-Sus JD, Sotomayor EM, Shah BD.
PMID: 28404221
Hematol Oncol Stem Cell Ther. 2017 Sep;10(3):99-115. doi: 10.1016/j.hemonc.2017.02.003. Epub 2017 Apr 06.

Mantle cell lymphoma is a clinically heterogeneous disease occurring within a heterogeneous patient population, highlighting a need for personalized therapy to ensure optimal outcomes. It is therefore critical to understand the benefits and risks associated with both intensive and...

Cite
Sandoval-Sus JD, Sotomayor EM, Shah BD. Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. Hematol Oncol Stem Cell Ther. 2017;10(3):99-115doi: 10.1016/j.hemonc.2017.02.003.
Sandoval-Sus, J. D., Sotomayor, E. M., & Shah, B. D. (2017). Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. Hematology/oncology and stem cell therapy, 10(3), 99-115. https://doi.org/10.1016/j.hemonc.2017.02.003
Sandoval-Sus, Jose D, et al. "Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine." Hematology/oncology and stem cell therapy vol. 10,3 (2017): 99-115. doi: https://doi.org/10.1016/j.hemonc.2017.02.003
Sandoval-Sus JD, Sotomayor EM, Shah BD. Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. Hematol Oncol Stem Cell Ther. 2017 Sep;10(3):99-115. doi: 10.1016/j.hemonc.2017.02.003. Epub 2017 Apr 06. PMID: 28404221.
Copy Download .nbib Format: NLM
Management of mantle cell lymphoma.

Annals of hematology

Meusers P, Hense J.
PMID: 10602892
Ann Hematol. 1999 Nov;78(11):485-94. doi: 10.1007/s002770050545.

No abstract available.

Cite
Meusers P, Hense J. Management of mantle cell lymphoma. Ann Hematol. 1999;78(11):485-94doi: 10.1007/s002770050545.
Meusers, P., & Hense, J. (1999). Management of mantle cell lymphoma. Annals of hematology, 78(11), 485-94. https://doi.org/10.1007/s002770050545
Meusers, P, and Hense, J. "Management of mantle cell lymphoma." Annals of hematology vol. 78,11 (1999): 485-94. doi: https://doi.org/10.1007/s002770050545
Meusers P, Hense J. Management of mantle cell lymphoma. Ann Hematol. 1999 Nov;78(11):485-94. doi: 10.1007/s002770050545. PMID: 10602892.
Copy Download .nbib Format: NLM
[Clinical features and treatment analysis of mantle cell lymphoma].

Zhonghua zhong liu za zhi [Chinese journal of oncology]

Wei N, Shen J, Wang J, Huang D, Fu L, Wu L, Cui H, Yang L, Wang Z.
PMID: 26887522
Zhonghua Zhong Liu Za Zhi. 2015 Nov;37(11):873-4.

No abstract available.

Cite
Wei N, Shen J, Wang J, et al. [Clinical features and treatment analysis of mantle cell lymphoma]. Zhonghua Zhong Liu Za Zhi. 2015;37(11):873-4
Wei, N., Shen, J., Wang, J., Huang, D., Fu, L., Wu, L., Cui, H., Yang, L., & Wang, Z. (2015). [Clinical features and treatment analysis of mantle cell lymphoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 37(11), 873-4.
Wei, Na, et al. "[Clinical features and treatment analysis of mantle cell lymphoma]." Zhonghua zhong liu za zhi [Chinese journal of oncology] vol. 37,11 (2015): 873-4.
Wei N, Shen J, Wang J, Huang D, Fu L, Wu L, Cui H, Yang L, Wang Z. [Clinical features and treatment analysis of mantle cell lymphoma]. Zhonghua Zhong Liu Za Zhi. 2015 Nov;37(11):873-4. Chinese. PMID: 26887522.
Copy Download .nbib Format: NLM
Limited-stage mantle cell lymphoma: not so different from advanced-stage.

Leukemia & lymphoma

Martin P, Shah B.
PMID: 22988842
Leuk Lymphoma. 2013 Feb;54(2):217-8. doi: 10.3109/10428194.2012.731053. Epub 2012 Oct 16.

No abstract available.

Cite
Martin P, Shah B. Limited-stage mantle cell lymphoma: not so different from advanced-stage. Leuk Lymphoma. 2012;54(2):217-8doi: 10.3109/10428194.2012.731053.
Martin, P., & Shah, B. (2013). Limited-stage mantle cell lymphoma: not so different from advanced-stage. Leukemia & lymphoma, 54(2), 217-8. https://doi.org/10.3109/10428194.2012.731053
Martin, Peter, and Shah, Bijal. "Limited-stage mantle cell lymphoma: not so different from advanced-stage." Leukemia & lymphoma vol. 54,2 (2013): 217-8. doi: https://doi.org/10.3109/10428194.2012.731053
Martin P, Shah B. Limited-stage mantle cell lymphoma: not so different from advanced-stage. Leuk Lymphoma. 2013 Feb;54(2):217-8. doi: 10.3109/10428194.2012.731053. Epub 2012 Oct 16. PMID: 22988842.
Copy Download .nbib Format: NLM
Case report: blastic Mantle Cell Leukemia.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Bilgir O, Bilgir F, Eliyatkin N, Calan M, Ercan IA, Isikyakar T, Sari F.
PMID: 21855414
Transfus Apher Sci. 2011 Oct;45(2):157-60. doi: 10.1016/j.transci.2011.07.010. Epub 2011 Aug 19.

The patient, who was being followed up for Mantle Cell Lymphoma, was diagnosed with Mast Cell Leukemia 2 years after receiving R-CHOP treatment. The results of flow cytometry, which was performed upon determining leucocytosis and detecting blasts in the...

Cite
Bilgir O, Bilgir F, Eliyatkin N, et al. Case report: blastic Mantle Cell Leukemia. Transfus Apher Sci. 2011;45(2):157-60doi: 10.1016/j.transci.2011.07.010.
Bilgir, O., Bilgir, F., Eliyatkin, N., Calan, M., Ercan, I. A., Isikyakar, T., & Sari, F. (2011). Case report: blastic Mantle Cell Leukemia. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 45(2), 157-60. https://doi.org/10.1016/j.transci.2011.07.010
Bilgir, Oktay, et al. "Case report: blastic Mantle Cell Leukemia." Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis vol. 45,2 (2011): 157-60. doi: https://doi.org/10.1016/j.transci.2011.07.010
Bilgir O, Bilgir F, Eliyatkin N, Calan M, Ercan IA, Isikyakar T, Sari F. Case report: blastic Mantle Cell Leukemia. Transfus Apher Sci. 2011 Oct;45(2):157-60. doi: 10.1016/j.transci.2011.07.010. Epub 2011 Aug 19. PMID: 21855414.
Copy Download .nbib Format: NLM
From Minimal Residual Disease to Maintenance Therapy: Optimizing Tools for Treatment of Mantle Cell Lymphoma.

Oncology (Williston Park, N.Y.)

Tallarico M, Smith SM.
PMID: 27083467
Oncology (Williston Park). 2016 Apr;30(4):361-2.

No abstract available.

Cite
Tallarico M, Smith SM. From Minimal Residual Disease to Maintenance Therapy: Optimizing Tools for Treatment of Mantle Cell Lymphoma. Oncology (Williston Park). 2016;30(4):361-2
Tallarico, M., & Smith, S. M. (2016). From Minimal Residual Disease to Maintenance Therapy: Optimizing Tools for Treatment of Mantle Cell Lymphoma. Oncology (Williston Park, N.Y.), 30(4), 361-2.
Tallarico, Michael, and Smith, Sonali M. "From Minimal Residual Disease to Maintenance Therapy: Optimizing Tools for Treatment of Mantle Cell Lymphoma." Oncology (Williston Park, N.Y.) vol. 30,4 (2016): 361-2.
Tallarico M, Smith SM. From Minimal Residual Disease to Maintenance Therapy: Optimizing Tools for Treatment of Mantle Cell Lymphoma. Oncology (Williston Park). 2016 Apr;30(4):361-2. PMID: 27083467.
Copy Download .nbib Format: NLM
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.

Leukemia & lymphoma

Dreyling M, Kluin-Nelemans HC, Beà S, Hartmann E, Salaverria I, Hutter G, Perez-Galan P, Roue G, Pott C, Le Gouill S, Cortelazzo S, Rule S, Hess G, Zaja F, Vitolo U, Szymczyk M, Walewski J, Ribrag V, Unterhalt M, Hermine O, Hoster E.
PMID: 21851218
Leuk Lymphoma. 2011 Dec;52(12):2226-36. doi: 10.3109/10428194.2011.600488. Epub 2011 Aug 18.

Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in virtually all cases. Clinically, MCL shows an aggressive clinical course...

Cite
Dreyling M, Kluin-Nelemans HC, Beà S, et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma. 2011;52(12):2226-36doi: 10.3109/10428194.2011.600488.
Dreyling, M., Kluin-Nelemans, H. C., Beà, S., Hartmann, E., Salaverria, I., Hutter, G., Perez-Galan, P., Roue, G., Pott, C., Le Gouill, S., Cortelazzo, S., Rule, S., Hess, G., Zaja, F., Vitolo, U., Szymczyk, M., Walewski, J., Ribrag, V., Unterhalt, M., Hermine, O., Hoster, E. (2011). Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leukemia & lymphoma, 52(12), 2226-36. https://doi.org/10.3109/10428194.2011.600488
Dreyling, Martin, et al. "Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network." Leukemia & lymphoma vol. 52,12 (2011): 2226-36. doi: https://doi.org/10.3109/10428194.2011.600488
Dreyling M, Kluin-Nelemans HC, Beà S, Hartmann E, Salaverria I, Hutter G, Perez-Galan P, Roue G, Pott C, Le Gouill S, Cortelazzo S, Rule S, Hess G, Zaja F, Vitolo U, Szymczyk M, Walewski J, Ribrag V, Unterhalt M, Hermine O, Hoster E. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma. 2011 Dec;52(12):2226-36. doi: 10.3109/10428194.2011.600488. Epub 2011 Aug 18. PMID: 21851218.
Copy Download .nbib Format: NLM
Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop.

Leukemia & lymphoma

Gordon LI, Bernstein SH, Jares P, Kahl BS, Witzig TE, Dreyling M.
PMID: 24512319
Leuk Lymphoma. 2014 Oct;55(10):2262-70. doi: 10.3109/10428194.2013.876634. Epub 2014 Apr 17.

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 resulting from the t(11;14) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. MCL remains a clinically challenging...

Cite
Gordon LI, Bernstein SH, Jares P, et al. Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2014;55(10):2262-70doi: 10.3109/10428194.2013.876634.
Gordon, L. I., Bernstein, S. H., Jares, P., Kahl, B. S., Witzig, T. E., & Dreyling, M. (2014). Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop. Leukemia & lymphoma, 55(10), 2262-70. https://doi.org/10.3109/10428194.2013.876634
Gordon, Leo I, et al. "Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop." Leukemia & lymphoma vol. 55,10 (2014): 2262-70. doi: https://doi.org/10.3109/10428194.2013.876634
Gordon LI, Bernstein SH, Jares P, Kahl BS, Witzig TE, Dreyling M. Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2014 Oct;55(10):2262-70. doi: 10.3109/10428194.2013.876634. Epub 2014 Apr 17. PMID: 24512319.
Copy Download .nbib Format: NLM
Watch and Wait in Mantle Cell Lymphoma.

Hematology/oncology clinics of North America

Lee C, Martin P.
PMID: 32861281
Hematol Oncol Clin North Am. 2020 Oct;34(5):837-847. doi: 10.1016/j.hoc.2020.06.002. Epub 2020 Jul 29.

Mantle cell lymphoma (MCL) is a biologically heterogeneous disease, and patients may experience a clinical course ranging from indolent to very aggressive. Observational studies suggest that a subset of patients can be safely observed for a period of months...

Cite
Lee C, Martin P. Watch and Wait in Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020;34(5):837-847doi: 10.1016/j.hoc.2020.06.002.
Lee, C., & Martin, P. (2020). Watch and Wait in Mantle Cell Lymphoma. Hematology/oncology clinics of North America, 34(5), 837-847. https://doi.org/10.1016/j.hoc.2020.06.002
Lee, Christina, and Martin, Peter. "Watch and Wait in Mantle Cell Lymphoma." Hematology/oncology clinics of North America vol. 34,5 (2020): 837-847. doi: https://doi.org/10.1016/j.hoc.2020.06.002
Lee C, Martin P. Watch and Wait in Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020 Oct;34(5):837-847. doi: 10.1016/j.hoc.2020.06.002. Epub 2020 Jul 29. PMID: 32861281.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries